Plant Name: Sanguisorba officinalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR2B; | |
| TSHR; | |
| TDP1; ALPI; BLM; P4HB; HPGD; HSD17B1; AKR1B1; ALDH1A1; ALOX15; APEX1; POLB; AOX1; | |
| GAA; MGAM; | |
| HTR3A; | |
| ABL1; MAPK1; EGFR; | |
| CA2; CA1; CA12; CA9; CA5B; CA5A; CA3; CA14; CA7; CA4; CA6; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| KDM4E; | |
| MAOA; | |
| F10; | |
| BACE1; | |
| HIF1A; TP53; | |
| FUT7; | |
| ABCG2; ABCC1; | |
| SLCO1B3; SLCO1B1; | |
| NPC1; LMNA; RAB9A; MAPT; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| 5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.822E-10 | 3.053E-07 | ALPI, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.867E-09 | 5.047E-06 | ABCC1, CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 7.651E-09 | 7.572E-06 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.626E-08 | 1.362E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.881E-08 | 1.901E-05 | ALOX15, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 3.769E-08 | 2.214E-05 | AKR1B1, ALDH1A1, CYP1A1, CYP1B1, CYP3A4, ESR1, HSD17B1 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.690E-08 | 3.177E-05 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, ESR1, HSD17B1, NPC1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.080E-07 | 5.471E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.488E-07 | 1.106E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.519E-07 | 1.822E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.379E-07 | 2.055E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.656E-07 | 2.456E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.101E-06 | 3.797E-04 | ABL1, APEX1, BLM, CYP1A1, CYP1B1, EGFR, ESR1, MAPK1, NPC1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.544E-06 | 7.588E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, TBXAS1 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 3.340E-06 | 9.568E-04 | ABCG2, ABL1, CA12, CA2, CA7, EGFR, ESR1, HIF1A, HTR2B, MAPK1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.085E-25 | 2.363E-21 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 4.260E-06 | 1.145E-03 | AKR1B1, ALDH1A1, ALOX15, CYP1A1, CYP1B1, CYP3A4, HIF1A, MAOA, NPC1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.565E-06 | 1.443E-03 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.840E-06 | 1.479E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.840E-06 | 1.479E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.172E-06 | 2.270E-03 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.172E-06 | 2.270E-03 | ESR1, ESR2 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.539E-05 | 5.521E-03 | ABL1, AKR1B1, APEX1, BLM, EGFR, MAPK1, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 2.746E-05 | 5.581E-03 | GAA, MGAM |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 2.746E-05 | 5.581E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.746E-05 | 5.581E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 2.768E-05 | 5.581E-03 | CA3, HPGD, HTR3A, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.746E-05 | 5.581E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 2.746E-05 | 5.581E-03 | GAA, MGAM |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 2.974E-05 | 5.834E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.462E-05 | 6.499E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.597E-05 | 6.695E-03 | ABL1, AKR1B1, APEX1, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 3.814E-05 | 6.980E-03 | CYP1A2, EGFR, ESR1, ESRRA, HPGD |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.590E-05 | 8.192E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 5.212E-05 | 8.974E-03 | APEX1, BLM, POLB, TP53 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 5.212E-05 | 8.974E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.482E-05 | 9.043E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.482E-05 | 9.043E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 5.482E-05 | 9.043E-03 | GAA, MGAM |
| CC | GO:0043226; organelle | GO:0016604; nuclear body | 5.453E-05 | 9.043E-03 | ABL1, AOX1, APEX1, BLM, HIF1A, LMNA, MAPT, SMN1, SMN2, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.706E-19 | 4.141E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.565E-18 | 3.780E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.681E-25 | 1.096E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.664E-08 | 3.004E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.142E-07 | 6.244E-06 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.537E-07 | 3.128E-05 | CYP2C9; MAOA; ALOX15; HTR2B; MAPK1; HTR3A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.100E-06 | 3.841E-05 | MGAM; MAOA; GAA; ALOX15; AKR1B1; CYP3A4; CYP2C9; FUT7; HSD17B1; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; AOX1; ALPI |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.638E-07 | 3.128E-05 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.828E-06 | 3.841E-05 | CYP2C9; MAOA; CYP1A2; AOX1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.421E-06 | 3.970E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.108E-06 | 3.841E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.535E-06 | 3.841E-05 | CYP2C9; CYP1A2; ALOX15; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.309E-06 | 6.425E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.557E-05 | 6.228E-04 | MAPK1; TP53; HIF1A; EGFR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.086E-04 | 2.444E-03 | MAPK1; ESR1; EGFR; ESR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.372E-04 | 2.460E-03 | ABCC1; ABL1; CYP1B1; MAPK1; TP53; EGFR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.290E-04 | 3.174E-03 | MAPK1; TP53; HIF1A; ESR1; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.080E-04 | 3.717E-03 | MAPK1; TP53; ESR1; HIF1A |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.400E-04 | 2.460E-03 | MAPK1; TP53; EGFR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.049E-04 | 4.724E-03 | MAPK1; TP53; EGFR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.331E-04 | 3.738E-03 | HSD17B1; CYP1A1; CYP1B1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.863E-04 | 3.988E-03 | MAPK1; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.354E-04 | 6.669E-03 | MAPK1; TP53; EGFR |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.355E-05 | 1.180E-03 | MGAM; GAA; AKR1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.778E-04 | 6.682E-03 | MAPK1; TP53; EGFR |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.150E-04 | 6.075E-03 | CYP2C9; ALOX15; TBXAS1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.209E-03 | 7.929E-03 | MAPK1; TP53; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.259E-03 | 7.939E-03 | MAPK1; ESR1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.310E-03 | 7.956E-03 | ABL1; MAPK1; TP53 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.168E-03 | 1.224E-02 | ABL1; MAPK1; EGFR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.313E-03 | 1.224E-02 | MAPK1; TP53; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.311E-03 | 1.597E-02 | MAPK1; HIF1A; EGFR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.240E-03 | 1.224E-02 | HTR2B; MAPK1; EGFR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.252E-03 | 2.563E-02 | ABL1; MAPK1; HIF1A; TP53; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.499E-03 | 1.639E-02 | MAPK1; HIF1A; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.785E-03 | 2.714E-02 | MAPK1; MAPT; TP53; EGFR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.363E-03 | 2.255E-02 | ABL1; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.363E-03 | 2.255E-02 | ABCC1; MAPK1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.200E-03 | 3.056E-02 | LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.125E-03 | 2.782E-02 | MAPK1; TP53; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.342E-02 | 4.735E-02 | BACE1; MAPK1; MAPT |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.357E-02 | 4.735E-02 | MAPK1; HIF1A |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.444E-02 | 4.908E-02 | MAPK1; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 1.190E-02 | 4.335E-02 | MGAM; GAA |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.300E-03 | 1.597E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 2.864E-03 | 1.468E-02 | MAPK1; EGFR |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 7.475E-03 | 2.851E-02 | ABCC1; ABCG2 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 4.782E-03 | 2.119E-02 | MAOA; AOX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.080E-03 | 1.218E-02 | CA2; CA4 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.259E-03 | 1.940E-02 | POLB; APEX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.466E-02 | 4.908E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; TBXAS1 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; TBXAS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1; CA9; ABL1; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; CA1; CA9; ABL1; EGFR; ESR1; ESR1 |
| C00-D49: Neoplasms | Renal cancer | C64 | F10; CA9 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; EGFR; EGFR; EGFR; ESR1; ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; EGFR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA; MGAM |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| NA: NA | Christmas disease | NA | F10 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2B |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| NA: NA | Haemophilia B | NA | F10 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HTR3A; HTR3A |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ESRRA |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10 |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR3A; HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Edema | NA | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR3A |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| NA: NA | Vomiting | NA | HTR3A |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10 |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1; AKR1B1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; TBXAS1 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR3A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |